Immunocore : Regulation FD Disclosure - Form 8-K

Item 7.01.

Regulation FD Disclosure.

Domestic Issuer Status

Effective January 1, 2024, Immunocore Holdings plc (the "Company") will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a "foreign private issuer" as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January 1, 2024, the Company qualified as a foreign private issuer.

Disclosure Channels to Disseminate Information

The Company announces material information to the public about the Company, its product KIMMTRAK, its potential product candidates, its pipeline and the Company's IMMTAX platform and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission, press releases, public conference calls, the Company's website (www.immunocore.com), the investor relations section of its website (ir.immunocore.com), and/or social media, including its LinkedIn account (www.linkedin.com/company/immunocore) and X account (formerly known as "Twitter") (@Immunocore), in order to achieve broad, non-exclusionary distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. Please note that this list may be updated from time to time.